MENU
Articles by #hashtag

gedeonrichter

18 hits

Richter Acquires HELM’s Stakes in German Joint Ventures

D&T
Mar 6, 2024

Gedeon Richter Plc. has announced on the website of the Budapest Stock Exchange that it has signed an agreement with HELM AG, a Germany-based stock corporation (“HELM”) to buy 50% stake in Richter-Helm BioTec GmbH & Co. KG (“RHT”); and 30% stake in Richter-Helm BioLogics GmbH & Co. KG. (“RHB”) to become 100% owner of […]

Gedeon Richter Chairman of the Board Resigns

D&T
Feb 26, 2024

The Board of Directors of the Hungarian pharmaceutical company Gedeon Richter Plc. has informed the company’s shareholders in an extraordinary announcement that Erik Bogsch resigned from his position as Chairman of the Board with effect from March 1, 2024, while remaining a member of the Board. The Board of Directors accepted the resignation at its […]

Richter and Mithra Commercialize Drug in China

D&T
Dec 4, 2023

The Hungarian pharmaceutical company Gedeon Richter Plc. has announced on the website of the Budapest Stock Exchange that it expanded its partnership with Mithra Pharmaceuticals SA with a binding Head of Terms (HoT) agreement for the development and commercialization of the first estetrolbased combined oral contraceptive (15 mg estetrol (E4) / 3 mg drospirenone) and […]

EC Approves Commercialisation of Richter Preparation

D&T
Nov 2, 2023

The Hungarian pharmaceutical company Gedeon Richter Plc. - together with Sumitomo Pharma America, Inc. and Sumitomo Pharma Switzerland, GmbH - has announced on the website of the Budapest Stock Exchange that the European Commission has granted approval of a Type II Variation application for RYEQO® (relugolix 40 mg, estradiol 1.0 mg, and norethisterone acetate 0.5 […]

Richter and Mithra Sign Supply Agreement

D&T
Aug 8, 2023

The Hungarian pharma company Gedeon Richter Plc. and Mithra Pharmaceuticals of Belgium have signed a binding supply agreement for the active pharmaceutical ingredient (API) for the combined oral contraceptive Estelle® and Donesta®, a novel product candidate for the treatment of post-menopausal symptoms. The agreement, announced on the website of the Budapest Stock Exchange, specifies that […]

Richter's Revenue Increased, Profit Decreased

D&T
Aug 4, 2023

In the second quarter of this year, Gedeon RichterPlc. achieved a profit after tax of HUF 30.0 billion, 61.1% below the same period last year, in line with analysts' expectations, the pharmaceutical company announced on the website of the Budapest Stock Exchange (BSE) on Friday. Total revenue for the quarter was HUF 203.78 billion, up […]

Gedeon Richter Purchases Dutch Firm

D&T
Jul 20, 2023

The Hungarian pharmaceutical company Gedeon Richter Plc. and the Dutch IQ Medical Ventures B.V. have announced on the website of the Budapest Stock Exchange that they signed a Share Purchase Agreement to transfer 100% of the shares of Giskit MD B.V. to Richter from Giskit Holding B.V., the affiliate of IQ Medical. Giskit MD B.V. […]

Richter to Commercialize Product Portfolio in Brazil

D&T
May 23, 2023

Gedeon Richter Plc. has announced on the website of the Budapest Stock Exchange that its Brazilian affiliate Gedeon Richter do Brasil Importadora Exportadora e Distribuidora SA signed an agreement with Grünenthal do Brasil Farmaceutica Ltda on the commercialization of the latter‘s Women’s Healthcare portfolio. The portfolio includes oral contraceptives Belara and Belarina and food supplements […]

Gedeon Richter Reports Increased Profits

D&T
May 12, 2023

Quarterly operating profit growth was 10.1% without FX effects driven by favorable changes in the product portfolio mix and a relatively slower increase of operating expenses, the pharma company Gedeon Richter reports. In addition, no windfall tax was recorded in 2022 Q1. Excluding FX effects Richter’s gross profit increased by 15.3%, driven by a 17.4% […]

Gedeon Richter: Q4 Loss and Competitive Disadvantage

D&T
Feb 28, 2023

The Hungarian pharmaceutical company Gedeon Richter Plc. presented its results for the year 2022 this Tuesday. The report caused a price drop on the stock market, as it turned out that the always massively profitable company turned loss-making in the last quarter of the year (due to the special tax and the exchange rate change). […]

Richter and Mithra Sign Licence Agreement

D&T
Feb 15, 2023

Gedeon Richter Plc. and Mithra Pharmaceuticals have announced that they signed a license agreement for the commercialisation of Donesta®, a novel product candidate for the treatment of post-menopausal symptoms, according to a statement on the website of the Budapest Stock Exchange. The completion of the agreement follows the signing of the Binding Term Sheet by […]

Richter Acquires Company in Ireland

D&T
Feb 7, 2023

The Hungarian pharmaceutical company Gedeon Richter Plc. has announced on the website of the Budapest Stock Exchange that it has acquired from shareholders of Consilient Health 100% control of OC Distributors Ltd., an Ireland based company holding the marketing and distribution rights of a number of women’s healthcare products. The transaction value is GBP 32.5 […]

Pécs University: Funding for Unique Tool, R&D Center

D&T
Feb 3, 2023

The University of Pécs (PTE) and the pharma firm Gedeon Richter Plc. (Richter) are creating an infrastructure and professional knowledge base worth more than HUF five billion in cooperation, which can be used in the fields of pharmaceutical research and agricultural science, among others, and is also suitable for the structural analysis of macromolecules, the […]

HUF 28 Bn Special Tax by Gedeon Richter in 2022

D&T
Dec 27, 2022

The Hungarian pharmaceutical giant Gedeon Richter Plc. has published an extraordinary announcement on the website of the Budapest Stock Exchange that under a new government decree on the extra profit taxes, the magnitude of supplementary pharmaceutical tax payable by the company for the year 2022 is expected to be approximately HUF 28 billion. “On June […]

Further FDA Approval for Gedeon Richter Drug

D&T
Dec 19, 2022

The Hungarian pharma company Gedon Richter’s partner AbbVie has announced that the U.S. Food and Drug Administration (FDA) has approved VRAYLAR® (cariprazine) as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adults. Supported by clinical data demonstrating efficacy and well-established tolerability, this additional indication provides a new option for […]

© Copyright 2024 Duax Kft. –  All rights reserved.
sun